The eighteen incompatible medicaments and nineteen counteraction theory belongs to the category of compatibility contraindications in Traditional Chinese Medicine(TCM),and has been used as a basis for rational evaluation in the review and evaluation of TCM prescriptions for a long time.However,there is constant controversy on the theory from perspectives of the historical origins,content categories,modern research,clinical applications,and ancient and modern academic.Thus the author gathered opinions medical and pharmaceutical experts from various types of medical institutions across the country based on literature review,expert interviews,and questionnaire surveys.The improved Delphi method and evidence review evaluation system were used to classify and understand,the eighteen incompatible medicaments and nineteen counteraction theory in a hierarchical manner.The core principles of this theory were analyzed using a classification model of"toxic-toxic"combination,"toxic-non toxic"combination and"non toxic-non toxic"combination.The recommendations for clinical safety risk assessment were formed on various types of evidence.The final consensus consists of three parts and a total of 19 statements,aiming to provide reference for the scientific and rational use of herbal medicines and the high-quality development of the industry.

Objective To investigate the effect of aqueous extract of Scrophularia ningpoensis(AESN)on AMP-activated protein kinase(AMPK)activity in INS-1 cells under high glucose(HG)conditions.Methods INS-1 cells were cultured in HG medium and treated with different concentrations of AESN.The influences of AESN on cell viability and pyroptotic body formation were detected using the CCK-8 assay.Western blotting was used to observe the effects of AESN on AMPK expression and phosphorylation.The effect of AESN on AMPK activity was measured using time-resolved fluorescence resonance energy transfer(TR-FRET)assay.Results Compared with normal glucose controls,INS-1 cells exposed to HG showed decreased cell viabilities and increased formation of pyroptotic bubbles using CCK-8 assay.Western blotting results indicated that HG exposure led to a decrease in intracellular AMPK phosphorylation levels.However,co-incubation with AESN under HG exposure AESN treatment increased the cell viabilities and phosphorylation of AMPK and decreased the pyroptotic bubbles formation in a concentration-dependent manner.In addition,the results of TR-FRET revealed that AESN treatment effectively increased AMPK activity in a concentration-dependent manner.Conclusion AESN has an activating effect on AMPK activity in HG-treated INS-1 cells.

Objective To investigate the ameliorative effects and potential mechanism of Lithocarpus litseifoliu on renal function and inflammation in mice with hyperuricemic nephropathy(HN).Methods The HN model was established by the combined administration of adenine and potassium oxyzate.The mice were randomly divided into normal control group,model control group,benzbromarone group,and high,medium and low dose groups of Lithocarpus litseifoliu.Different drugs were given to the mice,and their body mass was recorded once a week.The levels of uric acid(UA),creatinine(Cr),urine protein(UP),blood urea nitrogen(BUN)and urine urea nitrogen(UUN)as well as the levels of tumor necrosis factor α(TNF-α)and interleukin 6(IL-6)in serum or urine of each group were collected and measured on the 21st day.Hematoxylin-eosin(HE)staining was performed to observe kidney tissue injury in mice;real-time PCR(RT-PCR)was performed to determine ATP-binding cassette subfamily G member 2(ABCG2),urate transporter protein(URAT1),glucose transporter protein 9(GLUT9),and cytosolic factor NF-κB p50(κB p50)in kidney tissues.Results Compared with the normal control group,the body mass of mice in the model control group was significantly lower after the second weeks of modeling(P＜0.05),and the levels of UA,Cr,UP,BUN,UUN,TNF-α,IL-6 contents and GLUT9 mRNA and κB p50 mRNA expression contents of kidney tissues were significantly higher(P＜0.01,P＜0.05).Compared with the model control group,the levels of Cr,UP,BUN and UUN contents and renal tissue nuclear cytokine κB p50 mRNA expression were significantly lower in the high,medium and low dose groups of Lithocarpus litseifoliu(P＜0.01,P＜0.05).The UA levels were significantly lower in the high dose group of Lithocarpus litseifoliu(P＜0.05),and renal ABCG2 mRNA expression was significantly higher in the medium dose group(P＜0.01).The renal URAT1 mRNA expression was significantly decreased in the low dose group(P＜0.01).Conclusion Lithocarpus litseifoliu has shown ameliorative effects on HN mice,and the mechanism may be related to the modulation of renal uric acid transporters,improvement of renal function and anti-inflammation effects.

Objective To explore esomeprazole(EMZ)on acetaminophen(APAP)pharmacokinetics and intestinal microbial balance.Methods A total of 14 rats were randomly allocated into two groups,with 7 rats in each group:acetaminophen group(APAP group),and acetaminophen+esomeprazole combination group(APAP+EMZ group),respectively.Rats in the combination group were fed in the metabolic cage.Equivalent 3.6 mg·kg-1·d-1 esomeprazole was administered intragastrically to the combination group for 14 days;Similarly,an equal volume of 0.9％sodium chloride soution(NaCl)was fed to the APAP group for 14 days.During this period,fecal samples were collected from the rats before and after 14 days of EMZ administration for microbial 16S rRNA sequencing.On the 15th day,both the APAP group and APAP+EMZ groups were administratered an equivalent of 44.82 mg·kg-1 APAP by the same method after the regular EMZ administration.The concentrations of APAP in rat plasma were determined by the UPLC-MS/MS method.Main pharmacokinetic parameters were processed and compared using the software DAS 3.0.1 and SPSS 24.0.Results The pharmacokinetic parameter Cmax of APAP was significantly different between APAP group and APAP+EMZ group(P＜0.05).Compared with APAP group,Cmax increased by 120.38％in the APAP+EMZ group.The pharmacokinetic parameters(AUC(0-∞)、CL、t 1/2、tmax)of APAP showed no statistical differences between APAP group and APAP+EMZ group(P＞0.05).The results of 16SrRNA of intestinal flora showed that the abundance of Lactobacillus,Bacteroides,Clostridium,and Escherichia decreased compared with that before drug administration,while the abundance of Bifidobacterium increased.However,the relative abundance of the above flora showed no prominent differences before and after the EMZ intervention(P＞0.05).Conclusions This study showed that when combining EMZ with APAP,the relative abundance of those related flora,which may influence the β-Glucuronidase,all changed to some extent,but made no difference in statistics.The effect of EMZ on the Cmax of APAP was statistically significant.However,the use of EMZ for two weeks did not alter the other pharmacokinetics of APAP by affecting the gut microbiota.

Objective To investigate the effects of total flavonoids from Vine tea on the intestinal flora of high-fat diet(HFD)induced non-alcoholic fatty liver disease(NAFLD)mice.Methods Twenty-eight mice were randomly divided into four groups:blank control group,model control group(HFD group),low-dose TF group(TF-L group),and high-dose TF group(TF-H group),with 7 mice in each group.Mice in the HFD group,TF-L group,and TF-H group were fed with high-fat diet(HFD)for 12 weeks,while those in the blank control group were fed a normal diet.After 12 weeks of high-fat diet feeding,mice in the TF-L group and TF-H group were orally administered TF solution at doses of 125 and 250 mg·kg-1·d-1 by gavage administration for 6 weeks of intervention.Pathological changes in the liver and intestine of mice were observed using hematoxylin-eosin(H&E)staining,and the expression levels of tight junction proteins between the epithelial cells of the colonic mucosa was analyzed by immunohistochemistry.ELISA kit was used to detect the level of serum inflammatory factors in mice.Changes of intestinal flora in mice were analyzed by 16S rRNA sequencing technology.Results Total flavonoids from Vine tea could effectively improve the pathological changes of liver and intestinal tract in mice,reduce the levels of serum inflammatory factors IL-6 and TNF-α,and promote the expression of tight junction proteins Occludin,ZO-1 and Claudin 1 in the colon.There were significant differences in the intestinal flora of the three groups of mice.Total flavonoids from Vine tea significantly decreased the ratio of Firmicutes to Bacteroidota(P＜0.05),increased the abundance of Faecalibaculum,Ligilactobacillus and Lactobacillus,which resulted in the improvement of intestinal flora disorders.Conclusion Total flavonoids from Vine tea have certain ameliorative effects on high-fat diet-induced NAFLD,and the mechanism may be related to the promotion of intestinal barrier repair and the improvement of intestinal flora disorders.

Objective To optimize the formula of Dahuang Xiaoshi decoction components based on its hepatoprotective activity and evaluate their efficacy.Methods The Wistar rats were randomly divided into blank group,model group,ursodeoxycholic acid group(positive group),and orthogonal groups of Dahuang Xiaoshi decoction components.The acute liver injury model induced by alpha-napthyl-i sothiocyanate(ANIT)was used to optimize the allocation ratio of Dahuang Xiaoshi decoction components by taking liver function indicators as an index and combining with multiple statistical methods.The additional Wistar rats were taken to induce liver injury and optimize the compatible dosage of Natrii Sulfas(0,1,2,4 g)in Dahuang Xiaoshi decoction components based on the biological signs and liver function biochemical indicators.On this basis,the Wistar rats were randomly divided into blank group,model group,ursodeoxycholic acid group and different dosages(low,medium and high)of the Zhibaihuang components group.The liver protective effect of Zhibaihuang components was systematically evaluated through the general biological signs,liver function biochemical indicators,lipid peroxide indicators,liver pathological examination and bile transport-related indicators.Results Dahuang Xiaoshi decoction components optimized by orthogonal and multiple statistics could improve the biological signs and ameliorate the biochemical abnormalities in rats with liver injury.Dahuang Xiaoshi decoction components combined with different dosages of Natrii Sulfas could slow down the mass loss of ANIT-induced acute liver injury rats(P＜0.01 or P＜0.05)and recall the abnormally elevated serum liver function enzyme activities(P＜0.01 or P＜0.05).Except for alkaline phosphatase(ALP),there was no statistical difference in regulating other liver function enzyme activity between different allocations of Natrii Sulfas.After comprehensive consideration,its composition was optimized to the Zhibaihuang components without Natrii Sulfas.Further pharmacodynamic evaluation results showed that the optimized Zhibaihuang components could improve their abnormal biological signs(P＜0.01 or P＜0.05),decrease the serum liver function enzyme activity(P＜0.01 or P＜0.05)and the levels of T-BiL and TG(P＜0.05),and restore the levels of hepatic lipid peroxide(P＜0.01 or P＜0.05),repair liver pathological injury,adjust the expression of bile transport proteins(P＜0.05),and thus exert good liver protective activity.Conclusion The optimized Dahuang Xiaoshi decoction components,Zhibaihuang components,was obtained through orthogonal,multiple statistics and univariate investigation.It could improve the abnormal biological signs of animals,protect the liver and reduce enzymes,resist lipid peroxidation,restore abnormal metabolic indicators,and repair liver pathological injury,which provides a reference for its further clinical application and development.

Objective To compare the approval status of orphan drugs in China and the United States(the U.S.)from 2018 to 2022,and to further understand the trends and reasons for the differences in the development of orphan drugs between the two countries.Methods Data on orphan drug approvals in China and the U.S.were retrieved from the National Medical Products Administration of China and the U.S.Food and Drug Administration(FDA),and the number,types,Marketing Authorisation Holder(MAH),target diseases,and new drugs marketed in China and the U.S.were classified and compared.Results From 2018 to 2022,426 approvals of orphan drugs in the U.S.and 63 approvals in China.Average annual growth rates of drug approval numbers in the U.S.and China were-4.81％and 8.38％,respectively.The most common types of orphan drugs approved in both countries were antineoplastic drugs and immunomodulators,of which 235(55.16％)were in the U.S.versus 15 types(23.81％)in China.Among the types of rare diseases targeted by these orphan drugs,the U.S.had the most rare tumor diseases(197 types,46.24％),while China had the most rare neurologrical and psychiatric diseases(22 types,34.92％).The U.S.marketed 36 first-in-class orphan drugs with breakthrough therapeutic value.And China marketed 40 innovative new drugs for the treatment of rare diseases.Conclusion The number of orphan drugs marketed in the U.S.has far surpassed that in China,but has shown a slight downward trend,while an increasing trend in China.The concentration of the domestic orphan drug industry in the U.S.is high,while China's orphan drugs still rely on imports.China has made substantial progress in making domestic innovative drugs for rare diseases,but there is a huge gap between China and the U.S.,especially in terms of advanced technology and innovative drugs.Therefore,intensify efforts should be made in the research and development(R & D)of new drugs for rare diseases in China,and actively participate in global synchronized research and development to achieve win-win cooperation.

Objective To strengthen the management of rational medication for patients with rare diseases and improve the level of comprehensive medication support,in order to address the pain points in medication for rare diseases.Methods By leveraging mobile information technology,a mobile application for the Guangdong Shortage Drug Consultation Platform was developed and a smart and multifunctional pharmaceutical service information platform for rare disease patients was established.Results As the first big data platform in China integrating provincial-level rare disease medical resources,it innovatively realizes the closed-loop interaction among"treatment to medication"online and offline by establishing a comprehensive and professional rare disease mobile pharmaceutical service system.Conclusion The pharmaceutical service platform builds a bridge for rare disease patients to seek medical treatment and and medicine,and helps promote the high-quality development of Healthy China strategy.

In recent years,in order to meet urgent clinical needs alleviate the shortage of rare disease drugs in China,a series of policies encouraging the research and development of rare disease drugs has been introduced.Enzyme replacement therapy(ERT)is a standard treatment for rare congenital metabolic disorders,especially for enzyme deficiency diseases.Due to the complexity and heterogeneity of drug molecules for rare enzyme replacement therapy,the evaluation of animal models is a major challenge in non-clinical development and evaluation.This article introduces the latest research progress in the development of rare enzyme replacement therapy drugs at home and abroad,put forward some thoughts and suggestions on the non-clinical evaluation(pharmacology,pharmacokinetics,and toxicology)of such products based on representative literature,combined with review practice.

The incidence of rare diseases is extremely low.But there are many kinds of rare diseases and most of them are serious and have poor prognosis.The lack of orphan drugs has always been a bottleneck in the field of rare disease treatment.Gene therapy,antibody therapy,enzyme replacement therapy and drug repurposing have gradually become key directions of orphan drug research and development with the advancement of genetic engineering,big data analysis and artificial intelligence.Although the research on rare diseases started late in China,it has received more and more attention in recent years.A series of measures have been taken to encourage pharmaceutical enterprises to actively participate in the research and development of orphan drugs,and have achieved rapid progress.This article analyzes the research progress of orphan drugs,and explores the driving force of developing orphan drugs,aiming to contribute to the future research and development of orphan drugs in China.